gemfibrozil has been researched along with raloxifene in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 6 (75.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Deguchi, T; Furuta, Y; Fusegawa, K; Hirouchi, M; Igeta, K; Ikenaga, H; Iwasaki, M; Izumi, T; Kurihara, A; Murata, S; Okazaki, O; Suzuki, N; Watanabe, N | 1 |
Ballard, TE; Henderson, JL; Kalgutkar, AS; Obach, RS; Orr, ST; Ripp, SL; Scott, DO; Sun, H | 1 |
Furukawa, T; Hosoya, K; Kadono, K; Moriguchi, H; Nakamori, F; Naritomi, Y; Teramura, T; Terashita, S; Tetsuka, K; Yamano, K | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
2 review(s) available for gemfibrozil and raloxifene
Article | Year |
---|---|
Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks.
Topics: Animals; Apoproteins; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Discovery; Drug Interactions; Heme; Humans; Models, Biological; Pharmacokinetics; Structure-Activity Relationship; Time Factors | 2012 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for gemfibrozil and raloxifene
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
Topics: Administration, Oral; Animals; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Area Under Curve; Cytochrome P-450 Enzyme System; Dogs; Drug Evaluation, Preclinical; Glucuronides; Glucuronosyltransferase; Half-Life; Humans; Macaca fascicularis; Male; Mice; Pharmaceutical Preparations; Predictive Value of Tests; Rats; Rats, Sprague-Dawley; Species Specificity | 2011 |
Quantitative prediction of human intestinal glucuronidation effects on intestinal availability of UDP-glucuronosyltransferase substrates using in vitro data.
Topics: Administration, Oral; Biotransformation; Cell Membrane Permeability; Cytochrome P-450 Enzyme System; Glucuronides; Glucuronosyltransferase; Humans; Intestinal Absorption; Intestines; Isoenzymes; Kinetics; Metabolic Clearance Rate; Microsomes; Models, Biological; Pharmaceutical Preparations; Recombinant Proteins; Substrate Specificity | 2012 |